close
close

Apre-salomemanzo

Breaking: Beyond Headlines!

Afcons Infrastructure IPO Day 1 Live Updates: Issue 10% Subscribed Check latest GMP, subscription status, etc.
aecifo

Afcons Infrastructure IPO Day 1 Live Updates: Issue 10% Subscribed Check latest GMP, subscription status, etc.

Afcons Infrastructure IPO Day 1 Live Updates: Shapoorji Pallonji Group’s flagship infrastructure engineering and construction company, Afcons Infrastructure Ltd, made its debut on D-Street today ‘today.

The first day of Afcons Infrastructure’s IPO showed poor performance. According to BSE data, the issue was 10% subscribed on its opening day.

The initial offer of shares attracted bids for 8,606,560 shares out of the 86,619,950 shares available, according to the BSE.

The retail investor segment recorded a subscription rate of 14%, while the quota for non-institutional investors was 11%. Qualified Institutional Buyers (QIBs) only subscribed 1%. The portion allocated to employees reached a subscription of 39%.

The company boasts a strong track record of delivering numerous complex, challenging and unique engineering, procurement and construction (EPC) projects, both in India and internationally. The price range for the Afcons Infrastructure IPO has been set between 440 and 463 per equity share with a par value of 10. The Afcons Infrastructure IPO subscription period is scheduled to begin on Friday, October 25 and close on Tuesday, October 29.

The IPO includes a new issue of equity shares valued at 1,250 crore and a share offering worth 4,180 crores by its promoter Goswami Infratech.

As of June 30, 2024, the firm is actively involved in 65 projects in 12 countries, with a cumulative order book estimated at 317.47 billion.

Over the years, the company has expanded its international presence, notably in Asia, Africa and the Middle East. Afcons Infrastructure has undertaken many complex, demanding, innovative and game-changing infrastructure projects in India and globally, as highlighted in the Fitch report.

Stay tuned for the latest GMP, subscription status, reviews, and more.